NDEV News Alert Brandquest Development Group Inc (NDEV) 0.2967

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Brandquest Development Group Inc (NDEV) 0.2967 $NDEV

12 Marijuana Stocks For Your Do Not 'Buy And Hold' List - Part V
Anthony Cataldo - at Seeking Alpha - Tue Jan 13, 1:03PM CST

GWPH: 78.09 (+1.70)

Marijuana Investments: Not Quite Yet
Dr. Harold Goldmeier - at Seeking Alpha - Fri Jan 09, 12:11PM CST


Novus MedPlan Progress Exceeds Expectations, Company Poised For Banner 2015
ACCESSWIRE - Tue Dec 30, 9:01AM CST
WHITEFISH, MT / ACCESSWIRE / December 30, 2014 / The rapid expansion of the cannabis industry has offered patients throughout the U.S. a ray of hope when it comes to treating a variety of conditions that medical marijuana (MMJ) is increasingly understood to be effective for. However, exorbitant costs for MMJ patients, associated with registration fees and other price pressures put on producers and distributors, have made MMJ treatments inaccessible to a sizeable portion of the market. This is why Novus Acquisition & Development Corp. (OTC: NDEV), created their innovative Novus MedPlan program, which offers MMJ patients a considerable discount on medicinals, as well as holistic and alternative medicines, using an exclusive provider network cost-savings model to grant members direct and easy access to the nearest providers in their state.
JNJ: 99.62 (+1.18), INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70)

Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point
ACCESSWIRE - Mon Dec 08, 9:21AM CST
WHITEFISH, MT / ACCESSWIRE / December 8, 2014 / A unique company in the MMJ space today that is focused on the medical insurance side of the business is Novus Acquisition & Development (OTC: NDEV). Novus provides health insurance and insurance related solutions to the growing wellness and MMJ markets using an innovative cost-saving provider network model that is administered via their wholly-owned Novus Medical Group subsidiary's Novus MedPlan. The timely rollout of the Novus MedPlan in states where MMJ is legal, which gives patients access to considerable discounts on MMJ products for a modest subscriber fee of under $20 a month, was recently highlighted in Forbes as the number one pick, taking the top slot out of a list of the eight hottest publicly traded companies to draw the interest of investors in this rapidly emerging sector.
CARA: 10.96 (-0.03), INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70)

American Cannabis Company, A Delaware Corporation, Joins The List Of At Least 46 Other Marijuana Stocks
Anthony Cataldo - at Seeking Alpha - Sun Dec 07, 5:36PM CST

GWPH: 78.09 (+1.70), FULL: 4.40 (+0.06)

Earth Science Tech's Pioneering CBD Work Spearheaded By Leading Cancer Treatment/Diagnostic Expert
ACCESSWIRE - Wed Nov 19, 3:07PM CST
WHITEFISH, MT / ACCESSWIRE / November 19, 2014 / A growing body of data from numerous studies over the past decade has gradually led to a more complete understanding of cannabinoid biology and pharmacology, including efficacy as an appetite stimulant, analgesic (pain reliever) and treatment for neurological disorders like epilepsy. Similar efficacy data regarding cannabinoids performing broad-spectrum anti-tumor functions and producing palliative effects on cancer symptoms, documented by the National Cancer Institute, has made cannabinoid science a hot property in the world of modern oncology medicine. Needless to say, the emerging market surrounding cannabinoids has been booming of late, with a variety of sector players seeing increased interest from investors, ranging from cannabis-based medicine developers like Cannabis Science (OTC: CBIS), to innovative medical cannabis-focused healthcare solution providers, like Novus Acquisition & Development (OTC: NDEV).
GWPH: 78.09 (+1.70)

Cannabis Legalization Wins Out in Midterm Elections
ACCESSWIRE - Mon Nov 10, 10:00AM CST
WHITEFISH, MT / ACCESSWIRE / November 10, 2014 / Cannabis stocks moved lower over the past week, according to data from the MarijuanaIndex(TM), despite favorable outcomes in the mid-term elections. Industry bellwethers, like GW Pharmaceuticals plc (NASDAQ: GWPH), traded largely sideways, although MedBox Inc. (OTC: MDBX) fell more than 20%.
GWPH: 78.09 (+1.70)

Novus MedPlan Cost-Saving Provider Network Offers A Strong Value Proposition
ACCESSWIRE - Fri Nov 07, 8:01AM CST
WHITEFISH, MT / ACCESSWIRE / November 7, 2014 / Marijuana reform was a key ballot initiative in seven states (as well as 17 municipalities and D.C.) this week, with more drug policy reform questions (most aimed at reforming or out outright repealing marijuana laws) on the ballot than at any time in the history of the country. In California, Proposition 47 was passed, transforming the lowest-level non-violent crimes like simple drug possession, from a felony to a misdemeanor, freeing up an estimated $1B per annum to be dedicated to useful things like crime prevention, school funding, mental health treatment, and victim services. Regulatory reforms like this are opening up sizable markets for both private and public sector participants.
GWPH: 78.09 (+1.70)

Novus MedPlan Passes Major Milestone With First Ever Medical Marijuana Cost Savings Plan
Marketwired - Wed Oct 15, 8:04AM CDT
Novus Acquisition & Development Corp (PINKSHEETS: NDEV), wholly owned subsidiary Novus Medical Group, Inc., a service provider of the health and wellness savings plan, "Novus MedPlan," is proud to announce that "Enrollment" has officially begun for patients looking to join the Novus MedPlan network.

Cannabis Industry Gears Up for Make-or-Break Moment in November
ACCESSWIRE - Tue Oct 14, 9:14AM CDT
Whitefish, MT / October 14, 2014 / Cannabis industry stocks moved lower last week, according to data from the Marijuana Index(TM), continuing its bearish 3-month trend alongside a broader decline affecting the U.S. stock market as a whole. Top gainers included MyECheck Inc. (OTC: MYEC), which jumped nearly 10% last week and 13% on Monday's session, after announcing a patent infringement lawsuit.

Neutra Corp Doubles but Cannabis Stocks Move Largely Lower Last Week
ACCESSWIRE - Mon Oct 06, 8:06AM CDT
Whitefish, MT / Oct 6, 2014 / Cannabis industry stocks moved lower last week, according to the Marijuana Index(tm). Top gainers included Neutra Corp. (OTC: NTRR), which soared more than 100%, after its joint venture partner Vertigo Technologies acquired Contain a Grow. Industry bellwether GW Pharmaceuticals plc (NASDAQ: GWPH) also moved higher later in the week after it was upgraded by Zacks from Neutral to Outperform.
INSY: 51.50 (-0.66), GWPH: 78.09 (+1.70)

Novus Offers Affordable Holistic Healthcare to Phoenix Area Patients Through Partnership With LifeGuard Wellness Clinic
Marketwire - Fri Oct 03, 7:00AM CDT
Novus Acquisition & Development Corp (PINKSHEETS: NDEV), wholly owned subsidiary Novus Medical Group, Inc., the service provider of the health and wellness savings plan, "Novus MedPlan," announces its partnership with LifeGuard Wellness Clinic, a holistic medical office serving the greater Phoenix, Arizona region.

Several Cannabis Stocks Report Significant Progress Last Week
ACCESSWIRE - Tue Sep 30, 8:00AM CDT
Whitefish, MT / September 30, 2014 / Cannabis industry stocks were mixed last week, despite ongoing regulatory gains both in the United States and around the world. Top gainers included MedBox Inc. (OTC: MDBX), which jumped more than 16% after launching its new website and completing its second capital raise, and Earth Science Tech Inc. (OTC: ETST), which jumped nearly 80% after announcing new CBD shipments and awareness efforts.

Novus/Vicente Sederberg Engagement Makes a Mile High Powerhouse
Marketwire - Thu Sep 25, 7:02AM CDT
Novus Acquisition & Development Corp. (PINKSHEETS: NDEV) ("Novus" or "the Company" , a provider of health care insurance related business through its subsidiary Novus Medical Group, Inc., today announced the engagement of the law firm Vicente Sederberg (Vicente) as its corporate legal advisor to assist with healthcare insurance in medical marijuana (MMJ) compliance issues. The law firm has extensive experience within the cannabis industry, playing an integral role in writing Colorado's Amendment 64 that established a legal marijuana market and serving on the Governor's task force to implement the law.

Novus Enters Into Exclusive Agreement With TKO Organics to Provide Medical Marijuana & Fulfillment Services to MedPlan Patients
Marketwire - Wed Sep 10, 7:03AM CDT
Novus Acquisition & Development Corp. (PINKSHEETS: NDEV) ("Novus" , a provider of health insurance and insurance-related services under the "MedPlan" brand through its subsidiary Novus Medical Group, Inc., today announced an agreement with TKO Reserve, LLC aka Turnkey Organics LLC. "TKO" to act as a third-party administrator of Novus' MedPlan, handling quality control, order processing, and delivery coordination to patients in Washington, Arizona, Oregon, California, Colorado, Nevada and Michigan.

Novus Hits A Major Milestone In Novus MedPlan Network
ACCESSWIRE - Tue Aug 26, 8:25AM CDT
Whitefish, MT / August 26, 2014 / Novus Medical Group, a wholly owned subsidiary of Novus Acquisition & Development (OTC: NDEV), has taken a significant step in building its Novus MedPlan network of providers for the rapidly growing medical marijuana industry. Novus MedPlan is being developed as a distinctive cost savings program that will offer its members cost savings of up to 50% on a range of wellness products and services, including hemp and medical marijuana products and services that are often not covered by traditional insurance. The company's recent Exclusive Provider Agreement with Nana's Secret, LLC, represents an important milestone for the program, tapping a popular line of products in the process of providing coverage in all medical marijuana states.

Novus Executes Provider Agreement With MMJ Beverage Company, Nana's Secret
Marketwire - Mon Aug 25, 7:05AM CDT
Novus Acquisition & Development Corp. (PINKSHEETS: NDEV) ("Novus" , developer of healthcare/insurance solutions targeting the medical marijuana industry through its wholly owned subsidiary Novus Medical Group, Inc., today announced the execution of an Exclusive Provider Agreement with Nana's Secret, LLC located in the State of Washington. Under the terms of the agreement, patients enrolled in the company's Novus MedPlan Benefit Package will receive an exclusive 30% discount on Nana's Secret full line of products.

Easton and GW Pharmaceuticals Lead Cannabis Stocks Higher Last Week
ACCESSWIRE - Tue Aug 19, 9:02AM CDT
WHITEFISH, MT / ACCESSWIRE / August 19, 2014 / The Marijuana Index(TM) moved marginally higher last week, driven by a 7.71% rise in GW Pharmaceuticals plc (NASDAQ: GWPH) shares, which was partially offset by a 15.3% drop in Medbox Inc. (OTC: MDBX) shares.
GWPH: 78.09 (+1.70), OGI.VN: 0.540 (+0.050)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading